Bispecific Antibody Improves PFS in EGFR-Mutated Lung Cancer

The HARMONi trial showed ivonescimab plus chemotherapy reduced disease progression risk by 48% in patients with EGFR-mutated NSCLC after TKI failure.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/bispecific-antibody-improves-pfs-egfr-mutated-lung-cancer-2025a1000nyr?src=rss

Author :

Publish date : 2025-09-10 18:55:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Bispecific Antibody Improves PFS in EGFR-Mutated Lung Cancer

‘Unprecedented’ Survival Seen With Maintenance Tarlatamab for SCLC in Early Study

DNA cassette tape can store every song ever recorded

Related Posts

Is Tylenol Linked to Infant Eczema?

Antibody Prevention of RSV in Infants; Medical Imaging and Cancer Risk in Kids

Trusted Vaccine Guidance Has Collapsed — Along With the Rule of Law

Considering GLP-1 Agonists for Patients With Psoriasis, HS

It’s Time to Get a Flu Vaccination. Here’s Who Needs One and Why.

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Is Tylenol Linked to Infant Eczema?

Antibody Prevention of RSV in Infants; Medical Imaging and Cancer Risk in Kids

Trusted Vaccine Guidance Has Collapsed — Along With the Rule of Law

Considering GLP-1 Agonists for Patients With Psoriasis, HS

It’s Time to Get a Flu Vaccination. Here’s Who Needs One and Why.

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Ahead of Shutdown, Most Americans Said They Wanted ACA Tax Credits Extended

Medical Groups Call for Physician Exemptions to Trump’s Executive Order

Categories

Archives